Drug Trial Radar · NCT07497880
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
306
Actual
Start
Apr 6, 2026
Primary completion
Jul 7, 2027
Study completion Jul 7, 2027
Sponsor
- Lead sponsor
- KaileraIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the efficacy of oral KAI-7535 once daily compared with placebo on percent change in body weight in participants living with obesity or overweight, with at least 1 weight-related comorbidity, without diabetes mellitus. Safety and tolerability and other weight-related outcomes will also be evaluated.
Conditions
- Obesity
- Overweight
Interventions
KAI-7535Drug
Oral tablets
PlaceboDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body Weight at Week 44 for Participants Without Diabetes MellitusTime frame: Baseline, Week 44
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
Kailera Clinical Site
Chandler, Arizona
Kailera Clinical Site
Phoenix, Arizona
Kailera Clinical Site
Irvine, California
Kailera Clinical Site
Lincoln, California
Kailera Clinical Site
Northridge, California
Kailera Clinical Site
Hamden, Connecticut
Kailera Clinical Site
Jacksonville, Florida
Kailera Clinical Site
Jupiter, Florida
Kailera Clinical Site
Palm Springs, Florida
Kailera Clinical Site
Pembroke Pines, Florida
Kailera Clinical Site
Decatur, Georgia
Kailera Clinical Site
Chicago, Illinois
Kailera Clinical Site
Skokie, Illinois
Kailera Clinical Site
South Bend, Indiana
Kailera Clinical Site
Kenner, Louisiana
Kailera Clinical Site
Garden City, Michigan
Kailera Clinical Site
Jefferson City, Missouri
Kailera Clinical Site
Kansas City, Missouri
Kailera Clinical Site
Spartanburg, South Carolina
Kailera Clinical Site
Knoxville, Tennessee
Kailera Clinical Site
Austin, Texas
Kailera Clinical Site
Austin, Texas
Kailera Clinical Site
Brownsville, Texas
Kailera Clinical Site
Farmers Branch, Texas
Kailera Clinical Site
Fort Worth, Texas
Kailera Clinical Site
Mesquite, Texas
Kailera Clinical Site
San Antonio, Texas
Kailera Clinical Site
San Antonio, Texas
Kailera Clinical Site
San Antonio, Texas
Kailera Clinical Site
Sugar Land, Texas
Kailera Clinical Site
Sandy City, Utah
Kailera Clinical Site
Dee Why, New South Wales, Australia
Kailera Clinical Site
Miranda, New South Wales, Australia
Kailera Clinical Site
Wollongong, New South Wales, Australia
Kailera Clinical Site
Norwood, South Australia, Australia
Kailera Clinical Site
Altona N., Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.